Lecleire S, Antonietti M, Di Fiore F, Ben-Soussan E, Bota S, Hellot M-F, Thiberville L, Michel P, Lerebours E, Ducrotté P
Department of Hepato-Gastroenterology and Nutrition, Rouen University Hospital & ADEN-EA3234/IFRMP23, Institute for Biomedical Research, Rouen, France.
Aliment Pharmacol Ther. 2007 Apr 15;25(8):955-63. doi: 10.1111/j.1365-2036.2007.03280.x.
Double stenting of oesophagus and airways may be required in palliative treatment of patients with locally advanced oesophageal cancer.
To assess feasibility, efficacy and complications occurring in patients with locally advanced oesophageal cancer receiving both oesophagus and airways stenting.
In one single centre between 1997 and 2005, among 180 patients with locally advanced oesophageal cancer treated by the palliative placement of a self-expanding metal stent, patients requiring double stenting of oesophagus and airways were identified. Clinical efficacy, complications and survival were retrospectively collected.
Fifteen patients (8.3% of 180) required a double stenting at follow-up. Symptomatic efficacy of oesophagus and airways stenting was 86.7% for dysphagia and 100% for dyspnoea. Median survival after the second stent insertion was 99 days. Life-threatening early complications occurred in three patients after double stenting (20%), including two deaths following oesophageal perforation and massive haemoptysis, respectively. Procedure-related mortality was 13.3%.
Double stenting of oesophagus and airways is feasible in patients with locally advanced oesophageal cancer, with a relevant clinical efficacy. However, early major complications including procedure-related death may occur in as many as 20% of patients. This treatment should be reserved to very selected patients with severe symptoms and end-stage disease.
局部晚期食管癌患者的姑息治疗可能需要对食管和气道进行双重支架置入。
评估接受食管和气道支架置入的局部晚期食管癌患者的可行性、疗效及并发症。
在1997年至2005年期间的一个单一中心,在180例接受自膨式金属支架姑息置入治疗的局部晚期食管癌患者中,确定需要对食管和气道进行双重支架置入的患者。回顾性收集临床疗效、并发症及生存情况。
15例患者(180例中的8.3%)在随访中需要进行双重支架置入。食管和气道支架置入对吞咽困难的症状缓解有效率为86.7%,对呼吸困难的有效率为100%。第二次支架置入后的中位生存期为99天。双重支架置入后有3例患者(20%)发生危及生命的早期并发症,包括分别因食管穿孔和大量咯血导致的2例死亡。与操作相关的死亡率为13.3%。
对局部晚期食管癌患者进行食管和气道双重支架置入是可行的,具有显著的临床疗效。然而,多达20%的患者可能会发生包括与操作相关死亡在内的早期严重并发症。这种治疗应仅用于症状严重且处于疾病终末期的经过严格筛选的患者。